Atreca (BCEL) Stock Forecast, Price Target & Predictions
BCEL Stock Forecast
Atreca stock forecast is as follows: an average price target of $4.00 (represents a 4344.44% upside from BCEL’s last price of $0.09) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
BCEL Price Target
BCEL Analyst Ratings
Atreca Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Nov 15, 2022 | - | Wedbush | $4.00 | $1.48 | 171.19% | 4344.44% |
Atreca Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $0.09 | $0.09 | $0.09 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Nov 15, 2022 | Wedbush | Outperform | Outperform | Hold |
Atreca Financial Forecast
Atreca Revenue Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 20 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | $59.77K | $63.36K | $67.16K | $71.19K | $75.47K | $80.00K | $216.67K |
High Forecast | $59.77K | $63.36K | $67.16K | $71.19K | $75.47K | $80.00K | $216.67K |
Low Forecast | $59.77K | $63.36K | $67.16K | $71.19K | $75.47K | $80.00K | $216.67K |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Surprise % | - | - | - | - | - | - | - |
Atreca EBITDA Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 20 | |
---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EBITDA | - | - | - | - | - | - | $-22.43M |
Avg Forecast | $-35.86K | $-38.01K | $-40.30K | $-42.72K | $-45.28K | $-48.00K | $-130.00K |
High Forecast | $-35.86K | $-38.01K | $-40.30K | $-42.72K | $-45.28K | $-48.00K | $-130.00K |
Low Forecast | $-35.86K | $-38.01K | $-40.30K | $-42.72K | $-45.28K | $-48.00K | $-130.00K |
Surprise % | - | - | - | - | - | - | 172.57% |
Atreca Net Income Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 20 | |
---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Net Income | - | - | - | - | - | - | $-23.01M |
Avg Forecast | $-9.44M | $-8.23M | $-8.62M | $-10.41M | $-13.77M | $-14.79M | $-25.46M |
High Forecast | $-9.44M | $-8.23M | $-8.62M | $-10.41M | $-13.22M | $-14.79M | $-25.46M |
Low Forecast | $-9.44M | $-8.23M | $-8.62M | $-10.41M | $-13.77M | $-14.79M | $-25.46M |
Surprise % | - | - | - | - | - | - | 0.90% |
Atreca SG&A Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 20 | |
---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
SG&A | - | - | - | - | - | - | $6.64M |
Avg Forecast | $1.29M | $1.36M | $1.45M | $1.53M | $1.62M | $1.72M | $4.66M |
High Forecast | $1.29M | $1.36M | $1.45M | $1.53M | $1.62M | $1.72M | $4.66M |
Low Forecast | $1.29M | $1.36M | $1.45M | $1.53M | $1.62M | $1.72M | $4.66M |
Surprise % | - | - | - | - | - | - | 1.42% |
Atreca EPS Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 20 | |
---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EPS | - | - | - | - | - | - | $-0.62 |
Avg Forecast | $-0.24 | $-0.21 | $-0.22 | $-0.26 | $-0.35 | $-0.38 | $-0.65 |
High Forecast | $-0.24 | $-0.21 | $-0.22 | $-0.26 | $-0.34 | $-0.38 | $-0.65 |
Low Forecast | $-0.24 | $-0.21 | $-0.22 | $-0.26 | $-0.35 | $-0.38 | $-0.65 |
Surprise % | - | - | - | - | - | - | 0.97% |
Atreca Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
PASG | Passage Bio | $0.60 | $6.00 | 900.00% | Buy |
BDTX | Black Diamond Therapeutics | $2.99 | $14.75 | 393.31% | Buy |
FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
RVMD | Revolution Medicines, Inc. Warrant | $55.87 | $58.57 | 4.83% | Buy |
BCEL Forecast FAQ
Is Atreca a good buy?
Yes, according to 1 Wall Street analysts, Atreca (BCEL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of BCEL's total ratings.
What is BCEL's price target?
Atreca (BCEL) average price target is $4 with a range of $4 to $4, implying a 4344.44% from its last price of $0.09. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Atreca stock go up soon?
According to Wall Street analysts' prediction for BCEL stock, the company can go up by 4344.44% (from the last price of $0.09 to the average price target of $4), up by 4344.44% based on the highest stock price target, and up by 4344.44% based on the lowest stock price target.
Can Atreca stock reach $0?
BCEL's average twelve months analyst stock price target of $4 supports the claim that Atreca can reach $0 in the near future.
What are Atreca's analysts' financial forecasts?
Atreca's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $155.47K (high $155.47K, low $155.47K), average EBITDA is $-93.28K (high $-93.28K, low $-93.28K), average net income is $-28.56M (high $-28.009M, low $-28.56M), average SG&A $3.35M (high $3.35M, low $3.35M), and average EPS is $-0.726 (high $-0.712, low $-0.726). BCEL's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $261.48K (high $261.48K, low $261.48K), average EBITDA is $-157K (high $-157K, low $-157K), average net income is $-36.711M (high $-36.711M, low $-36.711M), average SG&A $5.63M (high $5.63M, low $5.63M), and average EPS is $-0.933 (high $-0.933, low $-0.933).